Olmed Solutions: What Really Remains in UniGrd and Whether It Can Become a Deal
After the 2019 ProCOTID asset sale, Olmed did not retain an active UniGrd business. What remains is a focused carotid package: the carotid indication, FDA and TGA approvals, and a global license to use the related IP. That can still become a deal, but for now it is strategic optionality without production, marketing, or sales.
What Actually Remains in UniGrd
The main article made a simple point: Olmed's financing test will not be solved by clinical headlines alone. This follow-up isolates UniGrd because it sits in the report exactly where an alternative monetization source could appear. Not as an operating engine, but as an asset that might still become a transaction.
The core point is that UniGrd was not wiped out, but it was not retained intact either. After the 2019 transaction, ProCOTID sold the broader system's IP, inventory, equipment, and regulatory approvals, but it retained the exclusive rights and regulatory approvals for using the system in the carotid indication together with a carotid stent, the agreements tied to selling and marketing that excluded system, and an exclusive, global, perpetual, royalty-free, transferable license to use the IP related to that remaining package.
| After the 2019 sale | What it means in practice |
|---|---|
| The broader system package was sold | Olmed does not still own UniGrd in full |
| The carotid-indication rights and approvals were retained | What remains is narrow, but still commercial in character |
| An exclusive, global, perpetual, royalty-free, transferable IP-use license remained in place | This is more than a theoretical right. It is a framework that can, in principle, support development, production, commercialization, or a sale of the retained package |
The important detail is the type of asset that remains. This is not just leftover lab work, and it is not an active product line either. It is a focused carotid package that has already completed development, has already gone through human clinical testing, and still carries FDA approval from June 2015 and TGA approval from September 2016. In a medical-device company with no sales, that matters. A potential buyer would not be starting from zero, but would not be acquiring a self-running business either.
Why This Is Still Not a Live Business
This is where the report becomes very explicit. In the same disclosure stack that describes UniGrd, the company also says there is no marketing and no manufacturing of the product as of the report date, and that ProCOTID is not conducting production or marketing activity in practice. Anyone reading UniGrd as something already helping to finance Theroleaf is reading too fast.
The company also defines the monetization route it is actually pursuing: locating a buyer for the assets and IP rights tied to the system. Even in the product-line business objectives, the described target buyer is not a generic financial investor. It is an entity that already manufactures or markets carotid stents and wants to widen its portfolio to include embolic protection. That wording matters because it tells you the company is pointing to a tightly adjacent strategic transaction, not to an independent commercial restart.
| What gives UniGrd substance | What keeps it from being a live business |
|---|---|
| Completed development and existing regulatory approvals | No active production and no active marketing |
| A focused rights package that can be transferred or sold | No revenue base or active commercial channel around the product today |
| A relatively clear buyer profile: a player already active in carotid stents | No disclosed buyer, negotiation, or transaction timeline |
Competition also changes the character of the option. The company describes a market populated by large international players and still argues that UniGrd has technical advantages over systems marketed by Abbott and Medtronic, especially around remote locking, guidewire choice, and filter positioning. That can be read in two ways at once. On one hand, this is still a product the company believes has relevant differentiation. On the other hand, if a transaction is going to happen, it has to happen in a field already controlled by large players. That raises the bar. Retained rights alone are not enough. They still need to be valuable to someone who can actually use them.
What Could Turn It Into a Deal
The reason UniGrd still deserves a standalone follow-up is that the company has not pushed it to the margin. It includes a strategic transaction around the excluded system both in its business strategy and in its objectives for the coming months. That is not accidental wording. In a pre-commercial medical-device company, anything that earns a line in the next-year outlook is something management still wants the market to see as a live possibility.
But there is still a real gap between a live possibility and a deal. For UniGrd to move from a retained rights package to an economic event, four things have to line up at the same time: the buyer has to be strategic and field-specific, the narrower carotid package has to be enough even without the broader platform that was sold, the retained approvals and license have to save real time or risk for that buyer, and the technical differentiation the company stresses has to be worth money inside a competitive market.
| What could move a deal closer | Why it matters |
|---|---|
| A buyer that already lives in the carotid market | That is how the company itself describes the target buyer, so it is probably the realistic monetization path |
| Clear value in the retained approvals and license | That is the core of what remains, not an existing sales stream |
| A belief that the technical edge still matters | Without that, it is hard to see why an incumbent would pay for the package |
| A shift from intention language to process language | As long as the report only says the company is seeking a buyer, UniGrd remains an option rather than a transaction |
That also defines the right way to read UniGrd inside the broader financing story. It could matter a great deal to Olmed if it produces cash, a partnership, or even just proof that a strategic buyer exists for the asset. But until that happens, it does not actually reduce the company's dependence on equity financing and continuing clinical progress at Theroleaf. Put differently, this is an option worth tracking, not a funding bridge that already exists.
Conclusions
UniGrd remains inside Olmed as a narrower package than a first read might suggest, but also as a more live asset than it is easy to assume. It does not include the full system anymore, yet it does include a focused carotid indication, regulatory approvals, a global use license, and relevant sales-and-marketing agreements. Treating it as nothing would be a mistake. Treating it as an active business would be a different mistake.
Current thesis in one line: UniGrd is a real strategic option, but a narrow and unrealized one, so it can improve Olmed's funding story only if it moves from intention language into transaction language.
The strongest counter-thesis is straightforward: the retained package may simply be too narrow. Without production, without marketing, and in a market where large players already operate competing systems, the asset may remain visible in the report long before a real buyer appears.
What can change the market's reading in the short to medium term is not another generic line saying the company is seeking a buyer, but a concrete sign that there is a process, a partner, or a transaction structure that can start to be measured. Until then, UniGrd remains an asset that may matter a lot, but not one that belongs in the base case.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.